IRWDNasdaqPharmaceutical PreparationsUS GAAP · USD

Ironwood Pharmaceuticals, Inc

Ironwood Pharmaceuticals is a U.S.-based biopharmaceutical company focused on gastrointestinal therapies. Its core business is the commercialization of LINZESS in the U.S. through a collaboration with AbbVie, while it also develops apraglutide for short bowel syndrome and evaluates additional GI opportunities.

Kysy yhtiöstä
Liikevaihto47,7milj. USD
−47,3 %v/v
Liikevoitto (EBIT)98,5milj. USD
+5,8 %v/v
EBIT-marginaali206,5%
+103,6 %-yks.v/v
Nettotulos−2,3milj. USD
−358,6 %v/v
Vapaa kassavirta127milj. USD
+22,8 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−1 000−750−500−2500250500milj. USD2020: 117 milj. USD2020: EBIT 143 milj. USD20202021: 117 milj. USD2021: EBIT 232 milj. USD20212022: 107 milj. USD2022: EBIT 250 milj. USD20222023: 118 milj. USD2023: EBIT −945 milj. USD20232024: 91 milj. USD2024: EBIT 93 milj. USD20242025: 48 milj. USD2025: EBIT 99 milj. USD20254899
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: Ironwood Pharmaceuticals, Inc

Liiketoiminta

Osuus liikevaihdosta
Commercialized GI therapy75 %

Revenue tied to LINZESS commercialization in the U.S. through a collaboration with AbbVie.

Pipeline development programs15 %

Clinical development of apraglutide and other GI product candidates.

Collaborative arrangements and royalties10 %

License fees, milestones, and royalties from linaclotide partnerships outside the U.S.

Tuotteet

Raportoitu · osuus liikevaihdosta
99,8%FY2024100 %
  • Collaborative Arrangements99,8 %
  • Collaborative Arrangement Other Agreements0,2 %

Lähde: 10-K FY2024, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.

Asiakkaat

Ironwood sells primarily through a partner-led pharmaceutical model rather than direct end-customer sales. Its economic customers are patients and prescribers in gastrointestinal care, while revenue is driven by AbbVie’s commercialization of LINZESS and by partners that pay royalties, milestones, or license fees.

AbbVie collaboration partner

AbbVie commercializes LINZESS in the U.S. and shares net profits/losses with Ironwood.

Gastroenterology patients and prescribers

Patients and physicians using LINZESS for GI indications drive underlying product demand.

International licensees

Partners in Europe, Canada, Mexico, Japan, China and other markets pay royalties and fees on linaclotide.

Clinical development stakeholders

Regulators, investigators, and CDMOs support apraglutide development and approval efforts.

Strategia

Ironwood is concentrating on GI therapeutics, using LINZESS cash flows to support pipeline development and selective external innovation. Management is also exploring strategic alternatives while advancing apraglutide and other GI opportunities, reflecting a push to improve long-term growth and shareholder value.

Protect and extend LINZESS economicsLyhyt aikaväli

LINZESS remains the main revenue engine, so pricing, reimbursement, and partner execution are critical.

Advance apraglutide developmentKeskipitkä aikaväli

Apraglutide is the main pipeline asset and could diversify revenue beyond LINZESS if approved.

Evaluate strategic alternativesLyhyt aikaväli

Management is assessing options to maximize shareholder value amid pipeline and market uncertainty.

Maantiede

Ironwood is headquartered in the United States but now also has operations in Switzerland following the VectivBio acquisition. Its revenue base is still centered on the U.S. through LINZESS, while future upside and risk are tied to regulatory and commercial activity in Europe and other international markets.

Riskit

Ironwood is highly exposed to dependence on LINZESS and on AbbVie’s commercialization performance, so pricing pressure or channel fluctuations can quickly affect revenue. Pipeline risk is also elevated because apraglutide still needs additional clinical work and regulatory approval, while foreign operations and pharmaceutical regulation add compliance, currency, and execution risk.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Apraglutide clinical and regulatory uncertainty1Dependence on LINZESS and AbbVie collaboration2Drug pricing and reimbursement reform3Manufacturing and supply chain reliance on third parties4Foreign jurisdiction operating risk5
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Apraglutide clinical and regulatory uncertaintyVaikutus: KorkeaTodennäköisyys: Korkea

    FDA indicated a confirmatory Phase III trial is needed before NDA approval.

    Kohdistuu: Pipeline development

  2. Dependence on LINZESS and AbbVie collaborationVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Most revenue comes from U.S. LINZESS economics and settlement payments with AbbVie.

    Kohdistuu: U.S. commercial performance and partner execution

  3. Drug pricing and reimbursement reformVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Government action on pricing could lower realized net prices and profitability.

    Kohdistuu: U.S. and OECD pricing policy

  4. Manufacturing and supply chain reliance on third partiesVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Ironwood has no internal manufacturing or distribution capabilities.

    KohdistuuAPIFill-finishPackagingDistribution
  5. Foreign jurisdiction operating riskVaikutus: KeskitasoTodennäköisyys: Matala

    Switzerland and other non-U.S. activities create currency, legal, and compliance exposure.

    Kohdistuu: Basel and international operations

Kysy Clarifolta: Ironwood Pharmaceuticals, Inc

Kirjanpito

Harkinnanvaraiset erät
Revenue recognition for collaborations and licenses

Revenue depends on identifying performance obligations and timing of milestone/license recognition.

Vaikutus: Can shift revenue between periods and affect comparability

Sales reserves and rebate estimates

Management estimates governmental and contractual rebates and allowances.

Vaikutus: Can materially change collaboration revenue and net sales

Net profit share accounting for LINZESS

Reported revenue reflects net profits/losses after commercial expenses and partner settlements.

Vaikutus: Quarterly volatility in revenue and operating margin

Debt and financing cost accounting

Convertible notes and revolving credit facility create interest expense and non-cash amortization.

Vaikutus: Affects net income and cash flow presentation

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Arrowhead Pharmaceuticals, Inc

ARWR · Pharmaceutical Preparations

Oramed Pharmaceuticals Inc

ORMP · Pharmaceutical Preparations

Dogwood Therapeutics, Inc.

DWTX · Pharmaceutical Preparations

BioVie Inc

BIVIW · Pharmaceutical Preparations

Gilead Sciences, Inc

GILD · Biological Products, (No Diagnostic Substances)

Ardelyx, Inc

ARDX · Pharmaceutical Preparations

Päivitetty: 24.9.2026

Ironwood Pharmaceuticals, Inc (IRWD) liikevaihto, tulos ja tunnusluvut 2025 – Clarifo